Wednesday, October 7, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026, Sparking 60% Stock Surge

ON Semiconductor projected its AI data center revenue will double year-over-year in 2026 following a Q1 earnings beat. The stock climbed 60.1% over three months on the guidance. The signal points to widening outperformance for AI-focused chip names versus the broader semiconductor sector.

LM Salvado
LM Salvado

May 20, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026, Sparking 60% Stock Surge
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ON Semiconductor guided its AI data center revenue to double year-over-year in 2026, a forecast that sent the stock up 60.1% over the three months following its Q1 earnings beat.1

The guidance is one of the clearest demand signals yet from the chip supply chain. AI infrastructure buildout is accelerating, and component suppliers with direct data center exposure are pulling ahead of general semiconductor peers.

ON Semi's positioning matters. The company supplies power management and sensing chips used in AI server infrastructure. A revenue doubling projection in that segment reflects not just current orders but committed purchasing pipelines from hyperscalers.1

For traders, the divergence thesis is straightforward: AI-specific semiconductor exposure is outperforming the broader chip index. The test is whether AI data center segments at companies like ON Semi and Nvidia outpace the general semiconductor sector by more than 20% on revenue growth through Q3 2026.1

Macro conditions complicate the picture. The 10-Year US Treasury benchmark moved from 4.31 to 5, signaling tighter financial conditions.1 Rising rates typically compress valuations across growth equities. The exception has been high-growth AI names, where earnings acceleration has overridden multiple compression.

Convertible debt markets are also shifting. ON Semi's 2.50% Convertible Senior Notes saw a notable parameter drop, suggesting restructuring activity in AI-adjacent balance sheets.1 Companies are repositioning capital structures ahead of what they expect to be a sustained growth cycle.

The broader read for semiconductor investors: earnings guidance from AI-adjacent suppliers is now a leading indicator for the sector. When a company with direct hyperscaler exposure doubles its AI revenue forecast, the signal carries weight for the entire supply chain — from power delivery to advanced packaging to memory.

Q2 and Q3 results will test whether the guidance holds. If AI data center revenue tracks the doubling trajectory, expect further rotation into AI-specific chip names and continued underperformance from commodity semiconductor exposure.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com